The DOI matches its Crossref record; 113 of the 115 references it cites were found in a registry or an index.
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
Open accessPublished version of a preprint
Abstract
Previous meta-analyses have shown that the antidiabetic agent metformin is associated with reduced cancer incidence and mortality. However, this effect has not been consistently demonstrated in animal models and recent epidemiologic studies. We performed a meta-analysis with a focus on confounders and biases, including body mass index (BMI), study type, and time-related biases. We identified 71 articles published between January 1, 1966, and May 31, 2013, through Pubmed, ISI Web of Science (Science Citation Index Expanded), Embase, and the Cochrane library that were related to metformin and cancer incidence or mortality. Study characteristics and outcomes were abstracted for each study that met inclusion criteria. We included estimates from 47 independent studies and 65,540 cancer cases in patients with diabetes. Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52–0.90], although between-study heterogeneity was considerable (I2 = 88%). Cancer mortality was reduced by 34% (SRR, 0.66; 95% CI, 0.54–0.81; I2 = 21%). BMI-adjusted studies and studies without time-related biases also showed significant reduction in cancer incidence (SRR, 0.82; 95% CI, 0.70–0.96 with I2 = 76% and SRR, 0.90; 95% CI, 0.89–0.91 with I2 = 56%, respectively), albeit with lesser magnitude (18% and 10% reduction, respectively). However, studies of cancer mortality and individual organ sites did not consistently show significant reductions across all types of analyses. Although these associations may not be causal, our results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally. Clinical trials are needed to determine if these observations apply to nondiabetic populations and to specific organ sites. Cancer Prev Res; 7(9); 867–85. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“long-term use of metformin in type 2 diabetes patients has been linked to a decline in tumor incidence and a reduced rate of cancer-related deaths.192–196”
From Drug repurposing for cancer therapy (2024) · cites this paper as [192]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a more thorough analysis that included more data and accounted for heterogeneous comparators showed that overall cancer incidence was reduced by 31% and cancer mortality by 34% (Gandini et al., 2014).”
From Metformin as a tool to target aging (2016) · cites this paper as Gandini et al., 2014
In the citing paper
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Gandini et al., 2014
In the citing paper
“Extensive support for a protective effect of metformin against cancer has been provided by numerous, but not all studies (237, 238).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [237]
In the citing paper
“In a meta-analysis(255), metformin-treated diabetic patients had a 31% reduction in the incidence of cancer and a 34% reduction in cancer mortality after adjusting for body mass index(255).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [255]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Sáenz, A., Fernandez-Esteban, I., Mataix, A. L., Segura, M. A., Figuls, M. R. I., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 310
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Furthermore, metformin is the drug of choice in obese patients with diabetes because it reduces weight (3, 100), so its use is associated with obesity.”
Backgroundvon Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Cited by
Sorted by citations
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Epidemiology of Renal Cell Carcinoma: 2022 Update
Bukavina, L., Bensalah, K., Bray, F., Carlo, M. I., Challacombe, B. J., Karam, J. A., Kassouf, W., Mitchell, T. J., Montironi, R., O’Brien, T., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.019 · Cited by 838
Pimpin, L., Cortez‐Pinto, H., Negro, F., Corbould, E., Lazarus, J. V., Webber, L., & Sheron, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.011 · Cited by 720
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 563
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C. L., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 460
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Griffin, S. J., Leaver, J. K., & Irving, G. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4337-9 · Cited by 398
Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention
Song, M., & Chan, A. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.012 · Cited by 355
Gui, D. Y., Sullivan, L. B., Luengo, A., Hosios, A. M., Bush, L. N., Gitego, N., Davidson, S. M., Freinkman, E., Thomas, C. J., & Vander Heiden, M. G. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.006 · Cited by 323
Metformin: a review of its potential indications
Wang, Y., He, S., Feng, X., Cheng, J. Q., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 330
Common risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 331
Repurposing metformin for the prevention of cancer and cancer recurrence
Heckman‐Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 302
Self-citationDrug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 298
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Shlomai, G., Neel, B. A., LeRoith, D., & Gallagher, E. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4044 · Cited by 242
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 212
Senolytics and senostatics as adjuvant tumour therapy
Short, S. C., Fielder, E., Miwa, S., & von Zglinicki, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.056 · Cited by 207
Therapeutic interventions for aging: the case of cellular senescence
Soto-Gamez, A., & Demaria, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.004 · Cited by 192
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies
Zadra, G., Batista, J. L., & Loda, M. F. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0068 · Cited by 202
Epigenetic effects of metformin: from molecular mechanisms to clinical implications
Bridgeman, S. C., Ellison, G. C., Melton, P. E., Newsholme, P., & Mamotte, C. D. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13262 · Cited by 190
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Suh, S., & Kim, K. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0177 · Cited by 194
Obesity and cancer: mechanistic insights from transdisciplinary studies
Allott, E. H., & Hursting, S. D. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0400 · Cited by 187
Time‐related biases in pharmacoepidemiology
Suissa, S., & Dell’Aniello, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5083 · Cited by 190
Xu, X., Sun, Y., Cen, X., Shan, B., Zhao, Q., Xie, T., Wang, Z., Hou, T., Xue, Y., Zhang, M., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00858-3 · Cited by 171
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Gerstein, H. C., Pare, G., Hess, S., Ford, R. J., Sjaarda, J., Raman, K., McQueen, M., Lee, S., Haenel, H., & Steinberg, G. R. (2017) · Diabetes Care · doi:10.2337/dc16-1682 · Cited by 169
Turning back time with emerging rejuvenation strategies
Mahmoudi, S., Xu, L., & Brunet, A. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0206-0 · Cited by 171
Clinical implications of germline mutations in breast cancer: TP53
Schon, K. R., & Tischkowitz, M. D. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4531-y · Cited by 156
Thakur, S., Daley, B., Gaskins, K., Vasko, V. V., Boufraqech, M., Patel, D., Sourbier, C., Reece, J. M., Cheng, S.-Y., Kebebew, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3167 · Cited by 157
Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review
Harris, H. R., & Terry, K. L. (2016) · Fertility Research and Practice · doi:10.1186/s40738-016-0029-2 · Cited by 155
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes
Wang, C.-P., Lorenzo, C., Habib, S. L., Jo, B., & Espinoza, S. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.013 · Cited by 134
Rozengurt, E., Sinnett‐Smith, J. W., & Eibl, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0005-2 · Cited by 137
Hodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 131
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117
Epidemiology and burden of pancreatic cancer
Maisonneuve, P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.02.030 · Cited by 124
Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity
Horiuchi, T., Sakata, N., Narumi, Y., Kimura, T., Hayashi, T., Nagano, K., Liu, K., Nishibori, M., Tsukita, S., Yamada, T., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769380 · Cited by 119
Insights into the Link Between Obesity and Cancer
Ackerman, S. E., Blackburn, O. A., Marchildon, F., & Cohen, P. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0263-x · Cited by 121
Björnsdóttir, H. H., Rawshani, A., Rawshani, A., Franzén, S., Svensson, A., Sattar, N. A., & Guðbjörnsdóttir, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-73668-y · Cited by 109
Luengo, A., Sullivan, L. B., & Heiden, M. G. V. (2014) · BMC Biology · doi:10.1186/s12915-014-0082-4 · Cited by 111
Cuzick, J. M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30536-3 · Cited by 108
MYME investigators, Nanni, O., Amadori, D., DeCensi, A., Rocca, A., Freschi, A., Bologna, A., Gianni, L., Rosetti, F., Amaducci, L., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05070-2 · Cited by 105
Self-citationLee, C. G., Heckman‐Stoddard, B. M., Dabelea, D., Gadde, K. M., Ehrmann, D. A., Ford, L., Prorok, P. C., Boyko, E. J., Pi-Sunyer, X., Wallia, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1046 · Cited by 101
Self-citationMetformin role in Parkinson’s disease: a double-sword effect
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., Jabir, M. S., Negm, W. A., & Batiha, G. E. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04771-7 · Cited by 104
Repurposing old drugs to fight multidrug resistant cancers
Dinić, J., Efferth, T., García‐Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I. K., Rizzolio, F., Saponara, S., Spengler, G., & Tsakovska, I. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100713 · Cited by 102
Skinner, H. D., Hu, C., Tsakiridis, T. K., Santana-Dávila, R., Lü, B., Erasmus, J. J., Doemer, A., Videtic, G. M. M., Coster, J. R., Yang, A. X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2318 · Cited by 99
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
Rassaf, T., Totzeck, M., Backs, J., Bokemeyer, C., Hallek, M. J., Hilfiker‐Kleiner, D., Hochhaus, A., Lüftner, D., Müller, O. J., Neudorf, U., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01636-7 · Cited by 97
Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies
Acton, E. K., Willis, A. W., & Hennessy, S. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5547 · Cited by 101
Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment
Sui, X., Xu, Y., Wang, X., Han, W., Pan, H., & Xiao, M. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00577 · Cited by 95
Metformin: current clinical applications in nondiabetic patients with cancer
Chen, K., Li, Y., Guo, Z., Zeng, Y., Zhang, W., & Wang, H. (2020) · Aging · doi:10.18632/aging.102787 · Cited by 90
Obesity and Breast Cancer: Not Only a Risk Factor of the Disease
Chan, D. S. M., & Norat, T. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0341-9 · Cited by 96
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89
MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities
Pedroza‐Torres, A., Romero-Cordoba, S. L., Justo-Garrido, M., Salido-Guadarrama, I., Rodríguez‐Bautista, R., Montaño, S., Muñiz-Mendoza, R., Arriaga-Canon, C., Fragoso‐Ontiveros, V., Álvarez-Gómez, R. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01404 · Cited by 93
Old wine in new bottles: Drug repurposing in oncology
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172784 · Cited by 91
Vilar‐Gomez, E., Vuppalanchi, R., Desai, A. P., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15331 · Cited by 84
miRNA-Based Technologies in Cancer Therapy
Pagoni, M. N., Cava, C., Sideris, D. C., Avgeris, M., Zoumpourlis, V., Michalopoulos, I., & Drakoulis, N. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111586 · Cited by 93
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson
Chaiteerakij, R., Petersen, G. M., Bamlet, W. R., Rabe, K. G., Zhen, D. B., Burch, P. A., Leof, E. R., Roberts, L. R., & Oberg, A. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3511 · Cited by 83
Raimondi, S., Botteri, E., Munzone, E., Cipolla, C. M., Rotmensz, N., DeCensi, A., & Gandini, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30062 · Cited by 81
Self-citationInflammaging and Immunosenescence as Part of Skin Aging—A Narrative Review
Pająk, J., Nowicka, D., & Szepietowski, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097784 · Cited by 84
Ming, M., Sinnett‐Smith, J. W., Wang, J., Soares, H. P., Young, S. H., Eibl, G., & Rozengurt, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114573 · Cited by 78
Martı́n-Castillo, B., Pernas, S., Dorca, J., Álvarez, I., Torres‐Martínez, S., Pérez-García, J. M., Batista-López, N., Rodríguez‐Sánchez, C. A., Amillano, K., Domínguez, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26286 · Cited by 77
DeCensi, A., Puntoni, M., Gandini, S., Guerrieri‐Gonzaga, A., Johansson, H. A., Cazzaniga, M., Pruneri, G., Serrano, D., Schwab, M. G., Hofmann, U., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3141-1 · Cited by 78
Self-citationSun, L., Wu, Y., Chen, J., Zhong, J., Zeng, F., & Wu, S. (2018) · Theranostics · doi:10.7150/thno.30080 · Cited by 78
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Brunetti, O., Gnoni, A., Licchetta, A., Longo, V., Calabrese, A., Argentiero, A., Delcuratolo, S., Solimando, A. G., Gardini, A. C., & Silvestris, N. (2019) · Medicina · doi:10.3390/medicina55100707 · Cited by 75
The right place for metformin today
Schernthaner, G., & Schernthaner, G.-H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107946 · Cited by 81
Metabolic reprogramming and disease progression in cancer patients
Torresano, L., Nuevo‐Tapioles, C., Santacatterina, F., & Cuezva, J. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165721 · Cited by 73
Association of metformin use and cancer incidence: a systematic review and meta-analysis
O’Connor, L. E., Bailey‐Whyte, M., Bhattacharya, M., Butera, G., Hardell, K. N. L., Seidenberg, A. B., Castle, P. E., & Loomans-Kropp, H. A. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae021 · Cited by 78
Macrophages and T cells in metabolic disorder-associated cancers
Taranto, D., Kloosterman, D. J., & Akkari, L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00743-1 · Cited by 81
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
Vujic, I., Sanlorenzo, M., Posch, C., Esteve‐Puig, R., Yen, A., Kwong, A., Tsumura, A., Murphy, R. M., Rappersberger, K., & Ortiz‐Urda, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2824 · Cited by 66
Autophagy Modulators in Cancer Therapy
Buzun, K., Gornowicz, A., Lesyk, R., Bielawski, K., & Bielawska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115804 · Cited by 68
Diabetes mellitus and metformin in hepatocellular carcinoma
Fujita, K., Iwama, H., Miyoshi, H., Tani, J., Oura, K., Tadokoro, T., Sakamoto, T., Nomura, T., Morishita, A., Yoneyama, H., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i27.6100 · Cited by 68
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus
Bradley, M. C., Ferrara, A. M., Achacoso, N. S., Ehrlich, S. F., Quesenberry, C. P., & Habel, L. A. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0424 · Cited by 64
Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation
Tang, G., Guo, J., Zhu, Y., Huang, Z., Liu, T., Cai, J., Yu, L., & Wang, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4343 · Cited by 65
Metformin as an adjuvant in breast cancer treatment
Roshan, M. H. K., Shing, Y. K., & Pace, N. P. (2019) · SAGE Open Medicine · doi:10.1177/2050312119865114 · Cited by 63
Ochoa-González, F. D. L., Cervantes-Villagrana, A. R., Fernández-Ruiz, J. C., Nava-Ramirez, H. S., Hernandez-Correa, A. C., Enciso‐Moreno, J. A., & Castañeda‐Delgado, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150900 · Cited by 64
Rozengurt, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00357 · Cited by 67
Metformin-induced anticancer activities: recent insights
Safe, S. H., Nair, V., & Karki, K. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0271 · Cited by 62
Murff, H. J., Roumie, C. L., Greevy, R. A., Hackstadt, A. J., McGowan, L. D., Hung, A. M., Grijalva, C. G., & Griffin, M. R. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1058-4 · Cited by 65
The role of an anti-diabetic drug metformin in the treatment of endocrine tumors
Thakur, S., Daley, B., & Kłubo-Gwieździńska, J. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0083 · Cited by 66
Wan, G., Sun, X., Li, F., Wang, X., Li, C., Li, H., Yu, X., & Cao, F. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493214 · Cited by 57
Diabetes Mellitus and Colorectal Cancer Risk
Kallergi, A., Chambre, C., Duchemann, B., Fysekidis, M., & Bihan, H. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0274-5 · Cited by 61
Metformin and Colorectal Cancer
Higurashi, T., & Nakajima, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00622 · Cited by 63
Metformin therapy associated with survival benefit in lung cancer patients with diabetes
Wan, G., Yu, X., Chen, P., Wang, X., Pan, D., Wang, X., Li, L., Cai, X., & Cao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.8881 · Cited by 59
Targeting Adipokines in Obesity-Related Tumors
Pu, X., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685923 · Cited by 61
Metformin: A Dual-Role Player in Cancer Treatment and Prevention
Galal, M. A., Al-Rimawi, M., Hajeer, A., Dahman, H., Alouch, S. S., & Aljada, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074083 · Cited by 73
Glucose-deprivation increases thyroid cancer cells sensitivity to metformin
Bikas, A., Jensen, K. E., Patel, A. D., Costello, J. M., McDaniel, D. P., Kłubo-Gwieździńska, J., Ларін, О. С., Hoperia, V., Burman, K. D., Boyle, L., et al. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0402 · Cited by 63
He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59
Repurposing old drugs to chemoprevention: the case of metformin
Heckman‐Stoddard, B. M., Gandini, S., Puntoni, M., Dunn, B. K., DeCensi, A., & Szabo, E. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.009 · Cited by 61
Self-citationImpact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease
Forman, D. E., Kuchel, G. A., Newman, J. C., Kirkland, J. L., Volpi, E., Taffet, G. E., Barzilai, N., Pandey, A., Kitzman, D. W., Libby, P., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.038 · Cited by 64
Cancer Metabolism as a Therapeutic Target and Review of Interventions
Halma, M. T. J., Tuszyński, J. A., & Marik, P. E. (2023) · Nutrients · doi:10.3390/nu15194245 · Cited by 59
Cancer chemoprevention: signaling pathways and strategic approaches
Ren, J., Yan, G., Yang, L., Kong, L., Guan, Y., Sun, H., Liu, C., Liu, L., Han, Y., & Wang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02167-1 · Cited by 67
Metadata
- Authors
- Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E.
- Affiliations
- European Institute of Oncology (IT)
- Ente Ospedaliero Ospedali Galliera (IT)
- 3Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
- National Institutes of Health (US)
- National Cancer Institute (US)
- Corresponding author
- Szabo, Eva
- Venue
- Cancer Prevention Research
- Published
- 2014-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 867-885
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- PMC
- PMC4154969
- OpenAlex
- W1976655891
- Cited by
- 457
- References
- 115
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 34 · 2023: 37 · 2022: 47 · 2021: 43 · 2020: 40 · 2019: 43 · 2018: 43 · 2017: 41 · 2016: 43 · 2015: 28 · 2014: 10
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Prevention Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- metformin, cancer incidence, cancer mortality, diabetes mellitus, body mass index, confounding, antidiabetic drugs, chemoprevention
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
